As a policy trend in many jurisdictions around the world, health care data openness can effectively improve the level of public governance, drive innovation in the medical industry, and promote market competition in the medical industry to a certain extent. However, the process of opening up health care data often comes with the risk of competition. First, the opening of health care data may lead to more efficient and stable collusion in reaching and implementing collusion. Second, the opening of health care data will also lead to more exploitative and exclusive abuse in the health care industry. Third, the opening of health care data will also lead to the frequent occurrence of data-driven and leveraged mergers and acquisitions risks. In order to effectively eliminate competition risks, China should propose new anti-monopoly countermeasures. On the one hand, China should strengthen the legislative regulations on the opening of health and medical data, including the regulation concept of monopoly agreement should be adjusted from information transparency to the implementation of classification and classification, and the regulation of abuse of market dominance should pay attention to the quantification of market power and the identification of specific behaviors, so as to include operators' commitments in the regulation of data-driven mergers and acquisitions. On the other hand, China also needs to introduce a full-chain regulatory system that combines the dual effects of competition advocacy and law enforcement, in the form of prior routine market investigations and fair competition reviews, as well as a flexible in-process and after-action regulatory approach. In addition, it is also necessary for China to build a coordinated regulatory model across multiple departments. On the basis of emphasizing the fundamental position of competition policy, we should make full use of the power of social supervision to regulate the restrictive competition behavior in the process of health and medical data opening in a more comprehensive way, and improve the safety and innovation of health and medical data opening to the greatest extent. 健康医疗数据开放作为世界范围内多个司法辖区的政策趋向,能有效提高公共治理水平、驱动医疗行业创新,以及在一定程度上促进医疗行业的市场竞争。然而,健康医疗数据开放过程通常伴随着竞争风险。其一,健康医疗数据开放可能导致共谋的达成与实施更高效,以及共谋合意更加稳定。其二,健康医疗数据开放也会导致医疗行业的剥削性滥用与排他性滥用行为更加普遍。其三,健康医疗数据开放还会导致数据驱动类与杠杆并购类风险的频发。为了有效消除竞争风险,中国应提出新的反垄断应对方案。一方面,中国应强化健康医疗数据开放的立法规制,包括垄断协议规制理念应从调整信息透明度到实施分级分类,滥用市场支配地位的规制则需注重市场力量的量化与具体行为的识别,将经营者承诺前置纳入数据驱动型并购的规制中。另一方面,中国还需要导入全链条监管体系,以结合竞争倡导与执法的双重功效,具体表现为事前常规性市场调查与公平竞争审查双管齐下,以及构建弹性的事中与事后监管方式。此外,构建多部门的协同监管模式对中国而言同样必要。在强调竞争政策的基础地位上,充分借助社会监管的力量,较为全面地规制健康医疗数据开放过程中的限制竞争行为,最大程度提高健康医疗数据开放的安全性与创新性。
Read full abstract